Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development
Reference number: GID-TA10858
Expected publication date: TBC
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma.
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.